Decitabine-induced Apoptosis is Derived by Puma and Noxa Induction in Chronic Myeloid Leukemia Cell Line As Well As in PBL and is Potentiated by SAHA

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2010 Dec 15

PMID 21153863

Citations 14

Authors

Barbora Brodska

Petra Otevrelova

Ales Holoubek

Affiliations

Soon will be listed here.

Abstract

Restoration of cellular apoptotic pathways plays a crucial role in cancer therapy strategies. In a broad spectrum of anticancer drugs, epigenetic effectors are in the center of interest mostly because of potential reversibility of their action. Methylation status of the cells is influenced by methyltransferase inhibitor 2-deoxy-5'-azacytidine (decitabine, DAC), but higher concentrations of this agent cause a DNA-damage. In our study, tumor supressor p53-apoptotic pathway was activated in decitabine-induced cell death. Expression of p53-inducible BH3-only apoptotic proteins Puma and Noxa was elevated and large activation of executive caspases was observed. The extent of acetylation in the cell is affected by histonedeacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Combination of SAHA with decitabine brought synergistic effect on apoptosis triggering in CML-T1 cell line, but apoptosis as well as necrosis occurred also in normal peripheral blood lymphocytes. Therefore, promising potential of such combined therapy calls for more detailed investigation of unwanted effects in normal cells.

Citing Articles

Epigenetics and immunotherapy in colorectal cancer: progress and promise.

Dang T, Guan X, Cui L, Ruan Y, Chen Z, Zou H Clin Epigenetics. 2024; 16(1):123.

PMID: 39252116 PMC: 11385519. DOI: 10.1186/s13148-024-01740-9.

Synergistic cytotoxicity of decitabine and YM155 in leukemia cells through upregulation of SLC35F2 and suppression of MCL1 and survivin expression.

Chiou J, Chang L Apoptosis. 2023; 29(3-4):503-520.

PMID: 38066391 DOI: 10.1007/s10495-023-01918-1.

Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials.

Xu Y, Li P, Liu Y, Xin D, Lei W, Liang A Cancer Commun (Lond). 2022; 42(6):493-516.

PMID: 35642676 PMC: 9198339. DOI: 10.1002/cac2.12313.

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models.

Fang D, Tang Q, Kong Y, Rong T, Wang Q, Li N Cell Death Discov. 2021; 7(1):90.

PMID: 33941774 PMC: 8093284. DOI: 10.1038/s41420-021-00465-5.

Epigenetic modulation of FBW7/Mcl-1 pathway for lung cancer therapy.

Kim M, Chen G, Sica G, Deng X Cancer Biol Ther. 2020; 22(1):55-65.

PMID: 33336620 PMC: 7833779. DOI: 10.1080/15384047.2020.1856756.

References

Garrison S, Jeffers J, Yang C, Nilsson J, Hall M, Rehg J . Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis. Mol Cell Biol. 2008; 28(17):5391-402. PMC: 2519737. DOI: 10.1128/MCB.00907-07. View

Gore S . In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?. Leuk Res. 2009; 33 Suppl 2:S2-6. PMC: 10916704. DOI: 10.1016/S0145-2126(09)70226-7. View

Jabbour E, Issa J, Garcia-Manero G, Kantarjian H . Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008; 112(11):2341-51. PMC: 4784235. DOI: 10.1002/cncr.23463. View

Shang D, Liu Y, Matsui Y, Ito N, Nishiyama H, Kamoto T . Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin. Urology. 2008; 71(6):1220-5. DOI: 10.1016/j.urology.2007.11.029. View

de Bruyne E, Bos T, Schuit F, Van Valckenborgh E, Menu E, Thorrez L . IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood. 2010; 115(12):2430-40. DOI: 10.1182/blood-2009-07-232801. View

Seo S, Jin H, Lee H, Woo S, Kim E, Yoo D . Combined effects of sulindac and suberoylanilide hydroxamic acid on apoptosis induction in human lung cancer cells. Mol Pharmacol. 2007; 73(3):1005-12. DOI: 10.1124/mol.107.041293. View

Zheng Q, Ma L, Zhu W, Zhang Z, Tong T . p21Waf1/Cip1 plays a critical role in modulating senescence through changes of DNA methylation. J Cell Biochem. 2006; 98(5):1230-48. DOI: 10.1002/jcb.20838. View

Ito A, Lai C, Zhao X, Saito S, Hamilton M, Appella E . p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 2001; 20(6):1331-40. PMC: 145533. DOI: 10.1093/emboj/20.6.1331. View

Yamaguchi H, Woods N, Piluso L, Lee H, Chen J, Bhalla K . p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem. 2009; 284(17):11171-83. PMC: 2670122. DOI: 10.1074/jbc.M809268200. View

10.

Tamm I, Wagner M, Schmelz K . Decitabine activates specific caspases downstream of p73 in myeloid leukemia. Ann Hematol. 2005; 84 Suppl 1:47-53. DOI: 10.1007/s00277-005-0013-0. View

11.

Willis S, Adams J . Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol. 2005; 17(6):617-25. PMC: 2930980. DOI: 10.1016/j.ceb.2005.10.001. View

12.

Akgul C . Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci. 2008; 66(8):1326-36. PMC: 11131550. DOI: 10.1007/s00018-008-8637-6. View

13.

Li Q, Bartlett D, Gorry M, OMalley M, Guo Z . Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms. Mol Pharmacol. 2009; 76(5):1072-81. DOI: 10.1124/mol.109.056291. View

14.

Kalousek I, Brodska B, Otevrelova P, Roselova P . Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes. Anticancer Drugs. 2007; 18(7):763-72. DOI: 10.1097/CAD.0b013e3280adc905. View

15.

Chen L, Willis S, Wei A, Smith B, Fletcher J, Hinds M . Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005; 17(3):393-403. DOI: 10.1016/j.molcel.2004.12.030. View

16.

Ecke I, Petry F, Rosenberger A, Tauber S, Monkemeyer S, Hess I . Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res. 2009; 69(3):887-95. DOI: 10.1158/0008-5472.CAN-08-0946. View

17.

Kumagai T, Wakimoto N, Yin D, Gery S, Kawamata N, Takai N . Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer. 2007; 121(3):656-65. DOI: 10.1002/ijc.22558. View

18.

Scott S, Dong W, Ichinohasama R, Hirsch C, Sheridan D, Sanche S . 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. Leuk Res. 2005; 30(1):69-76. DOI: 10.1016/j.leukres.2005.05.010. View

19.

Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y . Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol. 2006; 26(7):2782-90. PMC: 1430330. DOI: 10.1128/MCB.26.7.2782-2790.2006. View

20.

Jain N, Rossi A, Garcia-Manero G . Epigenetic therapy of leukemia: An update. Int J Biochem Cell Biol. 2008; 41(1):72-80. PMC: 3833715. DOI: 10.1016/j.biocel.2008.10.006. View